Remicade (infliximab) reduces signs and symptoms of ulcerative colitis, inducing and maintaining clinical remission in these patients.
Remicade belongs to a class of drugs called tumor necrosis factor blockers, which suppress the immune system by blocking the activity of TNF, a substance that can cause inflammation and lead to autoimmune diseases.
Related Articles on Ulcerative Colitis:
Study: New Cytokine Provides Protection From Colitis
Study: P53, PUMA Independently Regulate IEC Apoptosis in Colitis
FDA Approves Wider Use of Lialda for Patients With Ulcerative Colitis
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
